1 Targeting Major of CNS Disorders Advances in Treatment May 5th, 2022 I Nasdaq: RLMD Disclosures Certain statements contained in this presentation or in other documents of Relmada Therapeutics, Inc. (the "Company"), along with certain statements that may be made by management of the Company orally in presenting this material, may contain "forward-looking statements." These statements can be identified by the fact that they do not relate strictly to historic or current facts. They use words such as "estimat ...

1 Targeting Major of CNS Disorders Advances in Treatment March 7, 2022 I Nasdaq: RLMD Disclosures Certain statements contained in this presentation or in other documents of Relmada Therapeutics, Inc. (the "Company"), along with certain statements that may be made by management of the Company orally in presenting this material, may contain "forward-looking statements." These statements can be identified by the fact that they do not relate strictly to historic or current facts. They use words such as "estimat ...

Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q4 2021 Results Conference Call March 23, 2022 4:30 PM ET Company Participants Tim McCarthy - IR, LifeSci Advisors Sergio Traversa - CEO Maged Shenouda - CFO Conference Call Participants Andrew Tsai - Jefferies Andrea Tan - Goldman Sachs Joon Lee - Truist Securities Yatin Suneja - Guggenheim Jay Olson - Oppenheimer Operator Greetings, and welcome to the Relmada Therapeutics Fourth Quarter and Full Year 2021 Earnings Call. At this time, all participants are in a liste ...

Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q3 2021 Earnings Conference Call November 11, 2021 4:30 PM ET Company Participants Tim McCarthy - LifeSci Advisors Sergio Traversa - CEO & Director Maged Shenouda - Chief Financial Officer Charles Ence - Chief Accounting & Compliance Officer Conference Call Participants Andrew Tsai - Jefferies Yatin Suneja - Guggenheim Securities Joon Lee - Truist Securities Andrea Tan - Goldman Sachs Jay Olson - Oppenheimer Operator Greetings and welcome Relmada Therapeutics Inc. Th ...

Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q2 2021 Earnings Conference Call August 10, 2021 4:30 PM ET Company Participants Timothy McCarthy - LifeSci Advisors Sergio Traversa - CEO & Director Charles Ence - Chief Accounting & Compliance Officer Charles Gorodetzky - Former Scientific Director, National Institute of Drug Abuse Addiction Research Center Conference Call Participants Marc Goodman - SVB Leerink Andrea Tan - Goldman Sachs Group Joon Lee - Truist Securities Jay Olson - Oppenheimer Eddie Hickman - Gu ...

1 Targeting Major Advances in Treatment of CNS Disorders June 2021 I Nasdaq: RLMD Disclosures Certain statements contained in this presentation or in other documents of Relmada Therapeutics, Inc. (the "Company"), along with certain statements that may be made by management of the Company orally in presenting this material, may contain "forward-looking statements." These statements can be identified by the fact that they do not relate strictly to historic or current facts. They use words such as "estimate," ...

Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q1 2021 Results Earnings Conference Call May 12, 2021 4:30 PM ET Company Participants Tim McCarthy - LifeSci Advisors Sergio Traversa - Chief Executive Officer Chuck Ence - Chief Accounting and Compliance Officer Conference Call Participants Andrew Tsai - Jefferies Joon Lee - Truist Yatin Suneja - Guggenheim Partners Jay Olson - Oppenheimer Operator Good afternoon, ladies and gentlemen. And thank you for standing by. Welcome to the Relmada Therapeutics Incorporated F ...

Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q4 2020 Earnings Conference Call March 23, 2021 4:30 PM ET Company Participants Tim McCarthy - LifeSci Advisors Sergio Traversa - Chief Executive Officer Maged Shenouda - Chief Financial Officer Conference Call Participants Andrew Tsai - Jefferies Marc Goodman - Leerink Joon Lee - Truist Securities Jay Olson - Oppenheimer Operator Greetings. Welcome to the Relmada Therapeutics Incorporated Fourth Quarter and Full Year 2020 Financial Results Conference Call. At this t ...

Targeting Major 2020 Corporate Presentation I CNS Disorders Advances in Treatment of December 2020 I Nasdaq: RLMD Disclosures Certain statements contained in this presentation or in other documents of Relmada Therapeutics, Inc. (the "Company"), along with certain statements that may be made by management of the Company orally in presenting this material, may contain "forward-looking statements." These statements can be identified by the fact that they do not relate strictly to historic or current facts. The ...

Targeting Major 2020 Corporate Presentation I CNS Disorders Advances in Treatment of November 2020 I Nasdaq: RLMD Disclosures Certain statements contained in this presentation or in other documents of Relmada Therapeutics, Inc. (the "Company"), along with certain statements that may be made by management of the Company orally in presenting this material, may contain "forward-looking statements." These statements can be identified by the fact that they do not relate strictly to historic or current facts. The ...